CVE-2018-5438Philips ISCV application prior to version 2.3.0 has an insufficient session expiration vulnerability where an attacker could reuse the session of a previously logged in user.
Updated under an hour ago ()
Does this affect you?
It affects philips intellispace_cardiovascular. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.44%, higher than 37% of scored CVEs.
Do this next
Free account, 1 product
Philips ISCV application prior to version 2.3.0 has an insufficient session expiration vulnerability where an attacker could reuse the session of a previously logged in user. This vulnerability exists when using ISCV together with an Electronic Medical Record (EMR) system, where ISCV is in KIOSK mode for multiple users and using Windows authentication. This may allow an attacker to gain unauthorized access to patient health information and potentially modify this information.
- CVSS
- 6.3 MEDIUM (v3.0, NVD)CVSS:3.0/AV:L/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:N
- Weakness (CWE)
- Not given
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.44% (percentile 37)
- Assigned by
- icscert
- NVD analysis
- Modified
- Record last updated
- Aug 5, 2024
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
philips intellispace_cardiovascular philips:intellispace_cardiovascular | through 2.3.0 | NVD |
References
- https://www.usa.philips.com/healthcare/about/customer-support/product-securityx-refsource-confirm, mitigation, vendor-advisory
- https://ics-cert.us-cert.gov/advisories/ICSMA-18-025-01x-refsource-misc, mitigation, third-party-advisory, us-government-resource
- http://www.securityfocus.com/bid/102847vdb-entry, x-refsource-bid, third-party-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.